Imaging the Neurochemistry of Alcohol and Substance Abuse

Neuroimaging Clinics of North America

Volumn 17, Issue 4, 2007, Pages 539-555

  Martinez, Diana ^a   Kim, Jong Hoon ^a   Krystal, John ^b   Abi Dargham, Anissa ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLSPIPERONE; 4 AMINOBUTYRIC ACID; AMPHETAMINE; BETA CIT I 123; BUPRENORPHINE; CARFENTANIL; CYCLOFOXY; DASB C 11; DESMETHOXYFALLYPRIDE F 18; EPIDEPRIDE; FLUMAZENIL; IOMAZENIL; METHAMPHETAMINE; METHYLPHENIDATE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; RACLOPRIDE C 11; SEROTONIN; TRACER; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; HEROIN DEPENDENCE; HUMAN; NEUROCHEMISTRY; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANCE ABUSE;

ALCOHOLISM; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 35649019170     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2007.07.004     Document Type: Review

References (97)

1. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20 3 (2000) 423-451
2. Logan J., Fowler J.S., Dewey S.L., et al. A consideration of the dopamine D2 receptor monomer-dimer equilibrium and the anomalous binding properties of the dopamine D2 receptor ligand, N-methyl spiperone. J Neural Transm 108 3 (2001) 279-286
3. Volkow N.D., Fowler J.S., Wolf A.P., et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147 6 (1990) 719-724
4. Volkow N.D., Fowler J.S., Wang G.J., et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14 2 (1993) 169-177
5. Volkow N.D., Wang G.J., Fowler J.S., et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386 (1997) 830-833
6. Martinez D., Broft A., Foltin R.W., et al. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 29 6 (2004) 1190-1202
7. Wang G.J., Volkow N.D., Fowler J.S., et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16 2 (1997) 174-182
8. Hietala J., West C., Syvalahti E., et al. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl) 116 3 (1994) 285-290
9. Volkow N.D., Wang G.J., Fowler J.S., et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20 9 (1996) 1594-1598
10. Volkow N.D., Chang L., Wang G.J., et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158 12 (2001) 2015-2021
11. Wang G.J., Volkow N.D., Logan J., et al. Brain dopamine and obesity. Lancet 357 9253 (2001) 354-357
12. Volkow N.D., Fowler J.S., and Wang G.J. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 13 5-6 (2002) 355-366
13. Melis M., Spiga S., and Diana M. The dopamine hypothesis of drug addiction: hypodopaminergic state. Int Rev Neurobiol 63 (2005) 101-154
14. 123I]IBZM SPECT. J Nucl Med 40 Suppl 5 (1999) 110P
15. Wu J.C., Bell K., Najafi A., et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 17 6 (1997) 402-409
16. Mawlawi O., Martinez D., Slifstein M., et al. Imaging human mesolimbic dopamine transmission with PET: I. Accuracy and precision of D2 parameter measurements in the ventral striatum. J Cereb Blood Flow Metab 21 9 (2001) 1034-1057
17. Drevets W.C., Gautier C., Price J.C., et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49 2 (2001) 81-96
18. Martinez D., Narendran R., Foltin R.W., et al. Amphetamine-induced dopamine release is markedly blunted in cocaine dependence and predictive of the choice to self administer cocaine. Am J Psychiatry 164 4 (2007) 622-629
19. Volkow N.D., Wang G.J., Begleiter H., et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry 63 9 (2006) 999-1008
20. Volkow N.D., Wang G.J., Fowler J.S., et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156 9 (1999) 1440-1443
21. Volkow N.D., Wang G.J., Fowler J.S., et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46 2 (2002) 79-82
22. Self D.W., Barnhart W.J., Lehman D.A., et al. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271 5255 (1996) 1586-1589
23. Khroyan T.V., Barrett-Larimore R.L., Rowlett J.K., et al. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther 294 2 (2000) 680-687
24. Shaham Y., Shalev U., Lu L., et al. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168 1-2 (2003) 3-20
25. Volkow N.D., Wang G.J., Telang F., et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26 24 (2006) 6583-6588
26. Wong D.F., Kuwabara H., Schretlen D.J., et al. Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology 31 12 (2006) 2716-2727
27. Voorn P., Vanderschuren L.J., Groenewegen H.J., et al. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 27 8 (2004) 468-474
28. 123I] beta-CIT SPECT. Am J Psychiatry 155 6 (1998) 832-834
29. Volkow N.D., Wang G.J., Fowler J.S., et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 14 3 (1996) 159-168
30. Wang G.J., Volkow N.D., Fowler J.S., et al. Cocaine abusers do not show loss of dopamine transporters with age. Life Sci 61 11 (1997) 1059-1065
31. Aronson S.C., Black J.E., McDougle C.J., et al. Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology (Berl) 119 2 (1995) 179-185
32. Satel S.L., Krystal J.H., Delgado P.L., et al. Tryptophan depletion and attenuation of cue-induced craving for cocaine. Am J Psychiatry 152 5 (1995) 778-783
33. Walsh S.L., Preston K.L., Sullivan J.T., et al. Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 14 6 (1994) 396-407
34. Jacobsen L.K., Staley J.K., Malison R.T., et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 157 7 (2000) 1134-1140
35. Zubieta J.K., Gorelick D.A., Stauffer R., et al. Increased μ opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2 11 (1996) 1225-1229
36. Gorelick D.A., Kim Y.K., Bencherif B., et al. Imaging brain μ-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 57 12 (2005) 1573-1582
37. Volkow N.D., Wang G.J., Maynard L., et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. Psychiatry Res 116 3 (2002) 163-172
38. Martinez D., Gil R., Slifstein M., et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58 10 (2005) 779-786
39. Heinz A., Siessmeier T., Wrase J., et al. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 161 10 (2004) 1783-1789
40. 18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 162 8 (2005) 1515-1520
41. Repo E., Kuikka J.T., Bergstrom K.A., et al. Dopamine transporter and D2-receptor density in late-onset alcoholism. Psychopharmacology (Berl) 147 3 (1999) 314-318
42. 123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 157 1 (2000) 127-129
43. Kuikka J.T., Repo E., Bergstrom K.A., et al. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients. Neurosci Lett 292 1 (2000) 57-59
44. McBride W.J., Chernet E., Dyr W., et al. Densities of dopamine D2 receptors are reduced in CNS regions of alcohol-preferring P rats. Alcohol 10 5 (1993) 387-390
45. Thanos P.K., Volkow N.D., Freimuth P., et al. Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem 78 5 (2001) 1094-1103
46. Munro C.A., McCaul M.E., Oswald L.M., et al. Striatal dopamine release and family history of alcoholism. Alcohol Clin Exp Res 30 7 (2006) 1143-1151
47. Tiihonen J., Vilkman H., Rasanen P., et al. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. Mol Psychiatry 3 2 (1998) 156-161
48. 11C]dihydrotetrabenazine and positron emission tomography. Ann Neurol 44 3 (1998) 326-333
49. Tiihonen J., Kuikka J., Bergström K., et al. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat Med 1 7 (1995) 654-657
50. Laine T.P., Ahonen A., Rasanen P., et al. Dopamine transporter availability and depressive symptoms during alcohol withdrawal. Psychiatry Res 90 3 (1999) 153-157
51. Heinz A., Ragan P., Jones D.W., et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry 155 11 (1998) 1544-1549
52. Heinz A., Goldman D., Jones D.W., et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22 2 (2000) 133-139
53. Heinz A., Jones D.W., Bissette G., et al. Relationship between cortisol and serotonin metabolites and transporters in alcoholism. [correction of alcoholism]. Pharmacopsychiatry 35 4 (2002) 127-134
54. Heinz A., Jones D.W., Mazzanti C., et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47 7 (2000) 643-649
55. Szabo Z., Owonikoko T., Peyrot M., et al. Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biol Psychiatry 55 7 (2004) 766-771
56. 11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 29 5 (2002) 509-515
57. 11)C]DASB imaging of serotonin transporters in patients with alcoholism. Alcohol Clin Exp Res 31 1 (2007) 28-32
58. Gilman S., Koeppe R.A., Adams K., et al. Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics. Ann Neurol 40 (1996) 163-171
59. 123]iomazenil. Am J Psychiatry 155 11 (1998) 1550-1555
60. Lingford-Hughes A.R., Acton P.D., Gacinovic S., et al. Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy. Br J Psychiatry 173 (1998) 116-122
61. 11C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls. Psychiatry Res 50 1 (1993) 1-13
62. 123I-iomazenil single photon emission tomography study. Alcohol Clin Exp Res 24 9 (2000) 1449-1455
63. Jalan R., Turjanski N., Taylor-Robinson S.D., et al. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut 46 4 (2000) 546-552
64. Staley J.K., Gottschalk C., Petrakis I.L., et al. Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. Arch Gen Psychiatry 62 8 (2005) 877-888
65. Krystal J.H., Staley J., Mason G., et al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry 63 9 (2006) 957-968
66. Pfefferbaum A., Lim K.O., Zipursky R.B., et al. Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. Alcohol Clin Exp Res 16 6 (1992) 1078-1089
67. Gueorguieva R., Wu R., Pittman B., et al. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry 61 11 (2007) 1290-1295
68. 11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 55 3 (2004) 255-262
69. Heinz A., Reimold M., Wrase J., et al. Correlation of stable elevations in striatal μ-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62 1 (2005) 57-64
70. Zubieta J., Greenwald M.K., Lombardi U., et al. Buprenorphine-induced changes in μ-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology 23 3 (2000) 326-334
71. 18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295 3 (2000) 1070-1076
72. Greenwald M.K., Johanson C.E., Moody D.E., et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28 11 (2003) 2000-2009
73. Greenwald M., Johanson C.E., Bueller J., et al. Buprenorphine duration of action: μ-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 61 1 (2007) 101-110
74. McCann U., Szabo Z., Scheffel U., et al. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352 9138 (1998) 1433-1437
75. 11C]WIN-35,428. J Neurosci 18 20 (1998) 8417-8422
76. Iyo M., Sekine Y., and Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann N Y Acad Sci 1025 (2004) 288-295
77. Chou Y.H., Huang W.S., Su T.P., et al. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: a SPECT study. Eur Neuropsychopharmacol 17 1 (2007) 46-52
78. Volkow N.D., Chang L., Wang G.J., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158 3 (2001) 377-382
79. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18 1 (1998) 419-427
80. Melega W.P., Raleigh M.J., Stout D.B., et al. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766 1-2 (1997) 113-120
81. Harvey D.C., Lacan G., and Melegan W.P. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Exp Brain Res 133 3 (2000) 349-358
82. Harvey D.C., Lacan G., Tanious S.P., et al. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871 2 (2000) 259-270
83. Wilson J.M., Kalasinsky K.S., Levey A.I., et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2 6 (1996) 699-703
84. Reneman L., de Win M.M., van den Brink W., et al. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol 20 2 (2006) 164-175
85. 123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 34 10 (1991) 3144-3146
86. Heinz A., and Jones D.W. Serotonin transporters in ecstasy users. Br J Psychiatry 176 (2000) 193-195
87. 11C]AFM. J Cereb Blood Flow Metab 22 11 (2002) 1377-1398
88. Reneman L., Booij J., de Bruin K., et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358 9296 (2001) 1864-1869
89. Semple D.M., Ebmeier K.P., Glabus M.F., et al. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry 175 (1999) 63-69
90. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14 6 (1994) 982-994
91. Ricaurte G.A., and McCann U.D. Assessing long-term effects of MDMA (Ecstasy). Lancet 358 9296 (2001) 1831-1832
92. 11C]DASB. Neuropsychopharmacology 30 9 (2005) 1741-1750
93. Buchert R., Thomasius R., Wilke F., et al. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 161 7 (2004) 1181-1189
94. Buchert R., Thomasius R., Petersen K., et al. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging 33 2 (2006) 188-199
95. 123I]beta-CIT SPECT study-preliminary report. Psychopharmacology (Berl) 159 3 (2002) 335-340
96. Narendran R., Frankle W.G., Keefe R., et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162 12 (2004) 2352-2359
97. Guo N., Hwang D.R., Lo E.S., et al. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 28 9 (2003) 1703-1711